Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Generon (Shanghai) Corporation

Request full access

Therapeutic recombinant proteins for cancer and autoimmune diseases

Huangpu, ChinaFounded 2004Biotech & Life Sciences

About Generon (Shanghai) Corporation

Generon (Shanghai) Corporation, which rebranded to Evive Biotech in June 2020, is a biotechnology company focused on developing novel biological therapeutics. Founded in 2004, the firm develops treatments for oncology and inflammatory disorders that are difficult to treat. The company's business model revolves around discovering, developing, and producing biomedicines, specifically therapeutic recombinant proteins, using advanced biotechnologies. It operates with a global outlook, aiming to serve both Chinese domestic and international markets by providing high-quality, affordable biomedicines that meet the regulatory standards of the SFDA, FDA, and EMA.

The company has established cGMP facilities and has operations in the United States, Singapore, and China. Its pipeline includes F-627, a treatment for chemotherapy-induced neutropenia (CIN), and F-652, which is being developed for alcoholic hepatitis (AH) and acute graft-versus-host disease (GVHD). In 2019, the U.S. FDA granted orphan drug status to F-652. In 2021, Evive Biotech and Dr. Xiaoqiang Yan formed a joint venture, ITabMed Ltd., to continue the development of products from the iTAb™ (immunotherapy antibody) platform, which focuses on creating bi- or tri-specific T cell engagers with improved safety profiles.

Source: Dealroom company data

At a glance

Status
Operational
Employees
9
Open positions
None listed
Dealroom signal
22.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Jun 2022 $70M $280M Sino Biopharmaceutical · Yifan Pharmaceutical ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Generon (Shanghai) Corporation website traffic

Latest recorded traffic for Generon (Shanghai) Corporation is 430 monthly website visits, up 760% over the last three months. Generon (Shanghai) Corporation's team grew 0% over the past year.

Latest monthly visits430 3-month web change+760% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Generon (Shanghai) Corporation in the Huangpu ecosystem

Live from Dealroom

The Generon (Shanghai) Corporation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later2 investors entered at this stage

  • Sino Biopharmaceutical
  • Yifan Pharmaceutical
Employees 9 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Generon (Shanghai) Corporation on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Generon (Shanghai) Corporation’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.